{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(4)"],"submitter":["Braun R"],"pubmed_abstract":["The prognosis of pancreatic ductal adenocarcinoma (PDAC) is exceedingly poor. Although surgical resection is the only curative treatment option, multimodal treatment is of the utmost importance, as only about 20% of tumors are primarily resectable at the time of diagnosis. The choice of chemotherapeutic treatment regimens involving gemcitabine and FOLFIRINOX is currently solely based on the patient's performance status, but, ideally, it should be based on the tumors' individual biology. We established two novel patient-derived primary cell lines from surgical PDAC specimens. LuPanc-1 and LuPanc-2 were derived from a pT3, pN1, G2 and a pT3, pN2, G3 tumor, respectively, and the clinical follow-up was fully annotated. STR-genotyping revealed a unique profile for both cell lines. The populatio"],"journal":["Cells"],"pagination":["587"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9954561"],"repository":["biostudies-literature"],"pubmed_title":["Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response."],"pmcid":["PMC9954561"],"pubmed_authors":["Gorantla SP","Hael AAM","Busch H","Wellner UF","Lapshyna O","Castven D","Marquardt JU","Braun R","Konukiewitz B","Spielmann M","Keck T","Watzelt J","Farber B","Bolm L","Drenckhan M","Ungefroren H","Honselmann KC","Kunstner A"],"additional_accession":[]},"is_claimable":false,"name":"Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.","description":"The prognosis of pancreatic ductal adenocarcinoma (PDAC) is exceedingly poor. Although surgical resection is the only curative treatment option, multimodal treatment is of the utmost importance, as only about 20% of tumors are primarily resectable at the time of diagnosis. The choice of chemotherapeutic treatment regimens involving gemcitabine and FOLFIRINOX is currently solely based on the patient's performance status, but, ideally, it should be based on the tumors' individual biology. We established two novel patient-derived primary cell lines from surgical PDAC specimens. LuPanc-1 and LuPanc-2 were derived from a pT3, pN1, G2 and a pT3, pN2, G3 tumor, respectively, and the clinical follow-up was fully annotated. STR-genotyping revealed a unique profile for both cell lines. The populatio","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-03T22:18:13.269Z","creation":"2025-04-03T22:18:13.269Z"},"accession":"S-EPMC9954561","cross_references":{"pubmed":["36831254"],"doi":["10.3390/cells12040587"]}}